Volume 11, Issue 7 p. 757-771
Review

The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015

William J. Jagust

Corresponding Author

William J. Jagust

Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA

Corresponding author. Tel.: +1-510-643-6537.

E-mail address: [email protected]

Search for more papers by this author
Susan M. Landau

Susan M. Landau

Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA

Search for more papers by this author
Robert A. Koeppe

Robert A. Koeppe

Division of Nuclear Medicine, Department of Radiology, University of Michigan, Ann Arbor, MI, USA

Search for more papers by this author
Eric M. Reiman

Eric M. Reiman

Banner Alzheimer Institute, Phoenix, AZ, USA

Search for more papers by this author
Kewei Chen

Kewei Chen

Banner Alzheimer Institute, Phoenix, AZ, USA

Search for more papers by this author
Chester A. Mathis

Chester A. Mathis

Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA

Search for more papers by this author
Julie C. Price

Julie C. Price

Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA

Search for more papers by this author
Norman L. Foster

Norman L. Foster

Department of Neurology, Center for Alzheimer's Care, Imaging and Research, University of Utah, Salt Lake City, UT, USA

Search for more papers by this author
Angela Y. Wang

Angela Y. Wang

Department of Neurology, Center for Alzheimer's Care, Imaging and Research, University of Utah, Salt Lake City, UT, USA

Search for more papers by this author
First published: 01 July 2015
Citations: 153

Abstract

Introduction

This article reviews the work done in the Alzheimer's Disease Neuroimaging Initiative positron emission tomography (ADNI PET) core over the past 5 years, largely concerning techniques, methods, and results related to amyloid imaging in ADNI.

Methods

The PET Core has used [18F]florbetapir routinely on ADNI participants, with over 1600 scans available for download. Four different laboratories are involved in data analysis, and have examined factors such as longitudinal florbetapir analysis, use of [18F]fluorodeoxyglucose (FDG)-PET in clinical trials, and relationships between different biomarkers and cognition.

Results

Converging evidence from the PET Core has indicated that cross-sectional and longitudinal florbetapir analyses require different reference regions. Studies have also examined the relationship between florbetapir data obtained immediately after injection, which reflects perfusion, and FDG-PET results. Finally, standardization has included the translation of florbetapir PET data to a centiloid scale.

Conclusion

The PET Core has demonstrated a variety of methods for the standardization of biomarkers such as florbetapir PET in a multicenter setting.